Pre-admission warfarin use in patients with acute ischemic stroke and atrial fibrillation: The appropriate use and barriers to oral anticoagulant therapy

Thrombosis Research

Volumn 120, Issue 5, 2007, Pages 663-669

  Partington, Sara L ^a   Abid, Simona ^a   Teo, Koon ^a   Oczkowski, Wesley ^a   O'Donnell, Martin J ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ADULT; AGED; AGING; ALCOHOL CONSUMPTION; ANAMNESIS; ANTICOAGULATION; ARTICLE; BLEEDING; BLEEDING TENDENCY; CANADA; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG USE; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HUMAN; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; PREDICTION; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSIENT ISCHEMIC ATTACK; TREATMENT REFUSAL;

ACUTE DISEASE; ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 34547992312     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.12.019     Document Type: Article

References (22)

1. Kannel W.B., Abbott R.D., Savage D.D., and McNamara P.M. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med 306 (1982) 1018-1022
2. Wolf P.A., Abbott R.D., and Kannel W.B. Atrial fibrillation as an independent risk factor for stroke. Stroke 22 (1991) 983-988
3. Hart R.G., Benavente O., McBride R., and Pearce L.A. Antithrombic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131 7 (1999) 492-501
4. CQIN Investigators. Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation. In: Teo K.K. (Ed). Canadian Journal of Cardiology vol. 14, [5] (1998) 695-702
5. Bungard T.J., Ghali W.A., Teo K.K., McAlister F.A., and Tsuyuki R. Why do patients with atrial fibrillation not receive warfarin?. Arch Intern Med 160 (2000) 41-46
6. Beyth R.J., Antani M.R., Covinsky K.E., Miller D.G., Chren M.-M., Quinn L., et al. Why isn't warfarin prescibed to patients with nonrheumatic atrial fibrillation?. J Gen Intern Med 11 12 (1996 Dec) 768-770
7. Bungard T.J., Ghali W.A., McAlister F.A., Buchan A.M., Cave A.J., Hamilton P.G., et al. The relative importance of barriers to the prescription of warfarin for nonvalvular atrial fibrillation. Can J Cardiol 19 3 (2003) 280-284
8. Frykman V., Beerman B., Ryden L., and Rosenquist M. Management of atrial fibrillation: discrepancy between guideline recommendations and actual practise exposes patients to risk of complications. Eur Heart J 22 (2001) 1954-1959
9. Singer D.E., Albers G.W., Dalen J.E., Go A.S., Halperin J.L., and Manning W.J. Antithrombic therapy in atrial fibrillation. Chest 126 (2004) 429S-456S
10. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., and Radford M.J. Validation of clinical classification schemes for predicting stroke: results from a national registry of atrial fibrillation. JAMA 285 (2001) 2864-2870
11. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., and Hylek E. The pharmacology and management of the vitamin K antagonists. Chest 126 (2004) 204S-233S
12. Man-Son-Hing M., and Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch Intern Med 163 (2003) 1580-1586
13. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 154 (1994) 1449-1457
14. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 156 (1996) 409-416
15. Levine M.N., Raskob G., Beyth R.J., Kearon C., and Schulman S. Hemorrhagic complications of anticoagulant treatment. Chest 126 (2004) 287S-310S
16. Beyth R.J., Quinn L., and Landefeld S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 105 (1998) 91-99
17. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart association task force on practice guidelines. Circulation 112 12 (2005) e154-e235
18. Man-Son-Hing M., Nichol G., Lau A., and Laupacis A. Choosing antithrombic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 159 (1999) 677-685
19. Man-Son-Hing M., and Laupacis A. Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation. Arch Intern Med 162 (2002) 541-550
20. Perez I., Kalra L., and Melbourn A. Use of antithrombic measures for stroke in atrial fibrillation. Heart 82 (1999) 570-574
21. Devereaux P.J., Anderson D.R., Gardner M.J., Putman W., Flowerdew G.J., Brownell B.F., et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. Br Med J 323 (2001) 1-7
22. Douketis J.D., Johnson J.A., and Turpie A.G. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin. Arch Intern Med 164 (2004) 1319-1326